Allergan Korea's Botox Receives Extended Validity Period by KFDA

Published: 2005-03-30 06:56:00

Updated: 2005-03-30 06:56:00

Allergan Korea announced on March 28th that the Korea Food and Drug Administration (KFDA) approved for an extension of validity period for Botox (botulinum toxin type A) from the existing 2-year period to 3-year period.

According to Allergan Korea, the approval by the KFDA is reflective of the...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK